On January 4, 2022 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, reported that it will participate in the following conferences in January 2022 (Press release, Vivoryon Therapeutics, JAN 4, 2022, View Source [SID1234598012]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Bioconnect Conference

Date: January 10 − 13, 2022

Venue: virtual

Presenter: Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics

A webcast of the presentation will be available from Monday, January 10, 2022, at 7:00 am ET (1:00 pm CET) via the "Presentations & Webcasts" page in the Investor Relations section on the Company’s website at www.vivoryon.com and will be archived on the Company’s website for 30 days following the conference.

J.P. Morgan Health Care Conference

Date: January 10 − 13, 2022

Venue: virtual

Participants: Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO of Vivoryon Therapeutics